BRIACELL THERAPEUTICS CORP (BCT.CA) Fundamental Analysis & Valuation

TSX:BCT • CA1079303071

Current stock price

6.09 CAD
+0.18 (+3.05%)
Last:

This BCT.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. BCT.CA Profitability Analysis

1.1 Basic Checks

  • In the past year BCT has reported negative net income.
  • In the past year BCT has reported a negative cash flow from operations.
  • In the past 5 years BCT always reported negative net income.
  • BCT had a negative operating cash flow in each of the past 5 years.
BCT.CA Yearly Net Income VS EBIT VS OCF VS FCFBCT.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -88.22%, BCT is in line with its industry, outperforming 56.52% of the companies in the same industry.
  • With a decent Return On Equity value of -95.86%, BCT is doing good in the industry, outperforming 65.22% of the companies in the same industry.
Industry RankSector Rank
ROA -88.22%
ROE -95.86%
ROIC N/A
ROA(3y)-91.98%
ROA(5y)-72.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCT.CA Yearly ROA, ROE, ROICBCT.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 1K -1K 1.5K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for BCT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCT.CA Yearly Profit, Operating, Gross MarginsBCT.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. BCT.CA Health Analysis

2.1 Basic Checks

  • BCT has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, BCT has more shares outstanding
  • There is no outstanding debt for BCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BCT.CA Yearly Shares OutstandingBCT.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500K 1M 1.5M
BCT.CA Yearly Total Debt VS Total AssetsBCT.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

2.2 Solvency

  • BCT has an Altman-Z score of 1.42. This is a bad value and indicates that BCT is not financially healthy and even has some risk of bankruptcy.
  • BCT has a Altman-Z score of 1.42. This is in the better half of the industry: BCT outperforms 78.26% of its industry peers.
  • BCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.42
ROIC/WACCN/A
WACCN/A
BCT.CA Yearly LT Debt VS Equity VS FCFBCT.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M -20M

2.3 Liquidity

  • A Current Ratio of 10.10 indicates that BCT has no problem at all paying its short term obligations.
  • BCT has a Current ratio of 10.10. This is amongst the best in the industry. BCT outperforms 95.65% of its industry peers.
  • A Quick Ratio of 10.10 indicates that BCT has no problem at all paying its short term obligations.
  • BCT has a Quick ratio of 10.10. This is amongst the best in the industry. BCT outperforms 95.65% of its industry peers.
Industry RankSector Rank
Current Ratio 10.1
Quick Ratio 10.1
BCT.CA Yearly Current Assets VS Current LiabilitesBCT.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. BCT.CA Growth Analysis

3.1 Past

  • The earnings per share for BCT have decreased strongly by -184.87% in the last year.
EPS 1Y (TTM)-184.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.93%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 18.83% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y90.98%
EPS Next 2Y40.47%
EPS Next 3Y25.73%
EPS Next 5Y18.83%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BCT.CA Yearly Revenue VS EstimatesBCT.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2M 4M 6M 8M 10M
BCT.CA Yearly EPS VS EstimatesBCT.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 -50 -100 -150 -200

More info and screens

Find the best growth stocksShow best growing peers

1

4. BCT.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BCT. In the last year negative earnings were reported.
  • Also next year BCT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCT.CA Price Earnings VS Forward Price EarningsBCT.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCT.CA Per share dataBCT.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100 -150

4.3 Compensation for Growth

  • BCT's earnings are expected to grow with 25.73% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.47%
EPS Next 3Y25.73%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BCT.CA Dividend Analysis

5.1 Amount

  • No dividends for BCT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BCT.CA Fundamentals: All Metrics, Ratios and Statistics

BRIACELL THERAPEUTICS CORP

TSX:BCT (4/17/2026, 7:00:00 PM)

6.09

+0.18 (+3.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-10
Earnings (Next)06-15
Inst Owners1.05%
Inst Owner ChangeN/A
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap44.15M
Revenue(TTM)N/A
Net Income(TTM)-29.64M
Analysts80
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.04
P/tB 1.05
EV/EBITDA N/A
EPS(TTM)-175.98
EYN/A
EPS(NY)-4.71
Fwd EYN/A
FCF(TTM)-5.86
FCFYN/A
OCF(TTM)-5.86
OCFYN/A
SpS0
BVpS5.85
TBVpS5.82
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -88.22%
ROE -95.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-91.98%
ROA(5y)-72.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.1
Quick Ratio 10.1
Altman-Z 1.42
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-184.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.93%
EPS Next Y90.98%
EPS Next 2Y40.47%
EPS Next 3Y25.73%
EPS Next 5Y18.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-12.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y0.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.91%
OCF growth 3YN/A
OCF growth 5YN/A

BRIACELL THERAPEUTICS CORP / BCT.CA Fundamental Analysis FAQ

What is the fundamental rating for BCT stock?

ChartMill assigns a fundamental rating of 3 / 10 to BCT.CA.


What is the valuation status of BRIACELL THERAPEUTICS CORP (BCT.CA) stock?

ChartMill assigns a valuation rating of 1 / 10 to BRIACELL THERAPEUTICS CORP (BCT.CA). This can be considered as Overvalued.


How profitable is BRIACELL THERAPEUTICS CORP (BCT.CA) stock?

BRIACELL THERAPEUTICS CORP (BCT.CA) has a profitability rating of 1 / 10.


Can you provide the financial health for BCT stock?

The financial health rating of BRIACELL THERAPEUTICS CORP (BCT.CA) is 7 / 10.


What is the earnings growth outlook for BRIACELL THERAPEUTICS CORP?

The Earnings per Share (EPS) of BRIACELL THERAPEUTICS CORP (BCT.CA) is expected to grow by 90.98% in the next year.